Loading...

Photocure ASA

0IMT.L•LSE
HealthcareMedical - Pharmaceuticals
$50.30
$-0.20(-0.40%)

Photocure ASA (0IMT.L) Stock Overview

Explore Photocure ASA’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
4.94%
↑ 4.94%
Profit Growth
$0.02
↓ 591.32%
EPS Growth
$0.02
↓ 570.91%
Operating Margin
6.75%
↓ 26.64%
ROE
0.14%
↓ 591.32%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0IMT.LAnalyst Recommendations details for 0IMT.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

CEO

Mr. Daniel Schneider

Employees

99

Headquarters

Hoffsveien 4, Oslo

Founded

2011

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.